Dose-dense paclitaxel-containing adjuvant therapy for breast cancer

ONCOLOGY

Volumn 12, Issue 1 SUPPL.1, 1998, Pages 16-18

  Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; BREAST CANCER; CANCER CONTROL; CANCER RECURRENCE; CELL KILLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 0031939699     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992.
2. Frei IE, Canellos G: Dose. A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980.
3. Seidman A, Reichman B, Crown J, et al: Paclitaxel as second and subsequent therapy for inetastatic breast cancer: Activity independent of prior anthracycline response J Clin Oncol 13:1152-1159, 1995.
4. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995.
5. Ravdin P, Burris HI, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
6. Seidman A: Paclitaxel: The long and short of it Cancer J Sci Am 1:250-251, 1995.
7. Fisher B, Anderson S, Wickerham D, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997.
8. DeCillis A, Anderson S, Bryant J, et al: Acute myeloid leukemia (AML) and myelodys-plastic syndrome (MDS) on NSABP B-25: An update. Proc Am Soc Clin Oncol 16:130a, 1997.
9. Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28:1479-1499, 1971.
10. Hudis C: New approaches to adjuvant chemotherapy for breast cancer. Pharmacotherapy 16: 88s-93s, 1996.
11. Norton L: Kinetic concepts in the treatment of breast cancer. Recent Results Cancer Res 127:1-6, 1993.
12. Norton L: The Norton-Simon hypothesis in Perry MC (ed): The Chemotherapy Source Book, pp 36-53. Maryland, Williams & Wilkins, 1992.
13. Bonadonna G, Zambette M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273: 542-547, 1995.
14. Hudis C, Lebwohl D, Crown J, et al: Dose-intensive sequential crossover adjuvant chemotherapy for women with high risk node-positive primary breast cancer, in Sydney E Salmon (ed) Adjuvant Therapy of Cancer IV, pp 214-219. Philadelphia. JB Lippincott, 1993.
15. Riccio L, Hudis C, Seidman A, et al: Long-term distant disease-free survival (DPS) from 2 pilot studies of dose-dense (DD) sequential adjuvant chemotherapy (CRX) in women (PTS) with resected breast cancer (BC) and <3 positive lymph nodes (+LN). Proc Am Soc Clin Oncol 16:145a, 1997.
16. Hudis C, Seidman A, Baselga J, et al: Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 22(6; suppl 15):18-23, 1995.
17. Fennelly D, Schneider J, Spriggs D, et al: Dose escalation of Taxol with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly-sequenced high-dose carboplatin and cyclophosphamide courses. J Clin Oncol 13:1160-1166, 1995.
18. Hudis C, Seidman A, Raptis G, et al: Sequential dose-dense doxorubicin → paclitaxel → cyclophosphamide is less toxic than doxorubicin → concurrent paclitaxel + cyclophosphamide as adjuvant therapy in resected node positive breast cancer Proc Am Soc Clin Oncol 15:119, 1996.